Patents by Inventor Matthew Randolph Lee
Matthew Randolph Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11932633Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.Type: GrantFiled: May 6, 2019Date of Patent: March 19, 2024Assignees: Mirati Therapeutics, Inc., Array Biopharma Inc.Inventors: Matthew Arnold Marx, Matthew Randolph Lee, James F. Blake, Mark Joseph Chicarelli, Jay Bradford Fell, John P. Fischer, Erik James Hicken, Pavel Savechenkov, Tony Tang, Guy P. A. Vigers, Henry J. Zecca
-
Publication number: 20240066136Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.Type: ApplicationFiled: July 28, 2023Publication date: February 29, 2024Inventors: Jing LIU, Michael Bruno PLEWE, Matthew Randolph LEE, Xiaoran HAN, Liqun CHEN, Chengwei ZHANG, Jialiang WANG
-
Patent number: 11912719Abstract: The present invention relates to indoline-based compounds that inhibit Rho-associated protein kinase (ROCK) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.Type: GrantFiled: December 29, 2021Date of Patent: February 27, 2024Assignee: Cervello Therapeutics, LLC.Inventors: Matthew Randolph Lee, Anthony Joseph Varano, Jr., Thomas P. Bobinski
-
Publication number: 20230137025Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.Type: ApplicationFiled: August 26, 2022Publication date: May 4, 2023Inventors: Matthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
-
Publication number: 20230057177Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.Type: ApplicationFiled: October 7, 2021Publication date: February 23, 2023Inventors: Jing LIU, Michael Bruno PLEWE, Matthew Randolph LEE, Xiaoran HAN, Liqun CHEN, Chengwei ZHANG, Jialiang WANG
-
Patent number: 11485738Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.Type: GrantFiled: January 29, 2019Date of Patent: November 1, 2022Assignee: MIRATI THERAPEUTICS, INC.Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
-
Publication number: 20220119406Abstract: The present invention relates to indoline-based compounds that inhibit Rho-associated protein kinase (ROCK) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.Type: ApplicationFiled: December 29, 2021Publication date: April 21, 2022Inventors: Matthew Randolph Lee, Anthony Joseph Varano, JR., Thomas P. Bobinski
-
Patent number: 11267812Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.Type: GrantFiled: May 17, 2017Date of Patent: March 8, 2022Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.Inventors: John P. Fischer, Jay Bradford Fell, James F. Blake, Ronald Jay Hinklin, Macedonio J. Mejia, Erik James Hicken, Mark Joseph Chicarelli, John J. Gaudino, Guy P. A. Vigers, Laurence E. Burgess, Matthew Arnold Marx, James Gail Christensen, Matthew Randolph Lee, Pavel Savechenkov, Henry J. Zecca, Tony P. Tang
-
Patent number: 11248004Abstract: The present invention relates to indoline-based compounds that inhibit Rho-associated protein kinase (ROCK) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.Type: GrantFiled: May 5, 2020Date of Patent: February 15, 2022Assignee: Cervello Therapeutics, LLC.Inventors: Matthew Randolph Lee, Anthony Joseph Varano, Jr., Thomas P. Bobinski
-
Patent number: 11220509Abstract: The present disclosure relates to compounds of Formula (I), or pharmaceutically, acceptable salts thereof, that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present disclosure relates to compounds, or pharmaceutically acceptable salts thereof pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising compounds of Formula (I), or pharmaceutically acceptable salts thereof.Type: GrantFiled: March 31, 2021Date of Patent: January 11, 2022Assignee: MIRATI THERAPEUTICS, INC.Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
-
Publication number: 20210380570Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.Type: ApplicationFiled: May 6, 2019Publication date: December 9, 2021Inventors: Matthew Arnold Marx, Matthew Randolph Lee, James F. Blake, Mark Joseph Chicarelli, Jay Bradford Fell, John P. Fischer, Erik James Hicken, Pavel Savechenkov, Tony Tang, Guy P.A. Vigers, Henry J. Zecca
-
Patent number: 11091495Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions of the present invention.Type: GrantFiled: December 9, 2020Date of Patent: August 17, 2021Assignee: MIRATI THERAPEUTICS, INC.Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
-
Publication number: 20210230168Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.Type: ApplicationFiled: March 31, 2021Publication date: July 29, 2021Inventors: Matthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
-
Publication number: 20210101904Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.Type: ApplicationFiled: December 9, 2020Publication date: April 8, 2021Inventors: Matthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
-
Publication number: 20210032252Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.Type: ApplicationFiled: January 29, 2019Publication date: February 4, 2021Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
-
Publication number: 20200262844Abstract: The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.Type: ApplicationFiled: May 5, 2020Publication date: August 20, 2020Inventors: Matthew Randolph Lee, Anthony Joseph Varano, JR., Thomas P. Bobinski
-
Patent number: 10745381Abstract: The present invention relates to indoline-based compounds that inhibit Rho-associated protein kinase (ROCK) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.Type: GrantFiled: November 6, 2019Date of Patent: August 18, 2020Assignee: Cervello Therapeutics, LLC.Inventors: Matthew Randolph Lee, Anthony Joseph Varano, Jr.
-
Publication number: 20200140412Abstract: The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.Type: ApplicationFiled: November 6, 2019Publication date: May 7, 2020Inventors: Matthew Randolph Lee, Anthony Joseph Varano, JR.
-
Patent number: 10266542Abstract: The present invention relates to compounds that inhibit EZH2 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.Type: GrantFiled: March 14, 2018Date of Patent: April 23, 2019Assignee: Mirati Therapeutics, Inc.Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Robert Anthony Galemmo, Thomas P. Bobinski
-
Publication number: 20180265517Abstract: The present invention relates to compounds that inhibit EZH2 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.Type: ApplicationFiled: March 14, 2018Publication date: September 20, 2018Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Robert Anthony Galemmo, Thomas P. Bobinski